title: Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
abstract: Peptide receptor radionuclide therapy (PRRT) is a promising new treatment modality for inoperable or metastasized gastroenteropancreatic neuroendocrine tumors patients. Most studies report objective response rates in 15% to 35% of patients. Progression-free (PFS) and overall survival (OS) compare favorably with that for somatostatin analogues, chemotherapy, or newer, "targeted" therapies. Prospective, randomized data regarding the potential PFS and OS benefit of PRRT compared with standard therapies is anticipated.
authors.affiliation: Department of Nuclear Medicine, Erasmus MC, University Medical Center, s-Gravendijkwal 230, Rotterdam 3015CE, The Netherlands. Electronic address: d.j.kwekkeboom@erasmusmc.nl.
authors.forename: Dik J
authors.initials: DJ
authors.lastname: Kwekkeboom
authors.affiliation: Department of Nuclear Medicine, Erasmus MC, University Medical Center, s-Gravendijkwal 230, Rotterdam 3015CE, The Netherlands.
authors.forename: Eric P
authors.initials: EP
authors.lastname: Krenning
mesh_terms: D018572:Disease-Free Survival; D006801:Humans; D007414:Intestinal Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism / Q000532:radiotherapy*; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging / Q000378:metabolism / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism / Q000532:radiotherapy*; D011868:Radioisotopes / Q000378:metabolism / Q000627:therapeutic use; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000378:metabolism / Q000627:therapeutic use*; D018000:Receptors, Peptide / Q000378:metabolism; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism / Q000532:radiotherapy*
chemical_list: C504257:177Lu-octreotide, DOTA(0)-Tyr(3)-; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide; C496730:90Y-octreotide, DOTA-Tyr(3)-; D015282:Octreotide
keywords: Carcinoid; Neuroendocrine tumor; PRRT; Radionuclide therapy; Treatment